The stark reality of the opioid crisis in America is that more than 115 people die every day as a result of prescription painkillers, heroin and fentanyl.
To put that tragic statistic into context, more people die in one year from opioid overdoses than American lives lost during the entirety of the Vietnam War.
So, a medication with the potential to help in the fight against opioid addiction should be welcomed news, right?. This time, however, some observers are not so sure.
Richard Sackler, a member of the family that owns Purdue Pharma, creators of the opioid painkiller OxyContin, was awarded a patent in January 2018 for a new faster-acting type of buprenorphine, a drug used to treat opioid addiction.
STAT news contributor Andrew Joseph writes, “…the patent could enable Sackler to benefit financially from the addiction crisis that his family’s company is accused of fueling.”
Purdue Pharma Legal Issues
The drug-maker is already being sued in more than 1,000 counties around the country for its role in driving the opioid epidemic through misleading marketing that “OxyContin wasn’t addictive.”
In 2007, a federal court ruled that top executives at Purdue pay $630 million in fines for these crimes.
Those fines, though, did little to affect the $31 billion the company made from selling the painkiller that year.
Buprenorphine Opioid Drug Therapy
Buprenorphine, has shown much promise in opioid addiction treatment and is already on the market in different forms. The medication comes in pill form, a sublingual pill and even as time-release implants, called Probuphine.
Buprenorphine, which is only available by prescription, helps ease cravings and withdrawal symptoms in some of the following ways:
- This medication binds to opioid receptors in the body
- Opioid receptors are then satisfied, though without releasing high-levels of euphoric inducing dopamine or causing significant respiratory depression
- Buprenorphine also acts as something of a shield, blocking additional opioids from bonding with receptors, so that a person on the medication is unlikely to experience a “high” if they use heroin or prescription painkillers
Sackler’s patent application acknowledges the ongoing opioid crisis, and argues that a fast-dissolving buprenorphine wafer would prevent people from removing pills or the sublingual form of the medication from their mouths.
This could potentially aid in treatment and recovery if it’s eventually approved by the Federal Food and Drug Administration (FDA) and brought to market.
What Else is Being Done to Ease the Opioid Epidemic?
Other research is focused on creating non-addictive pain medications that could, potentially, end or limit the need for highly addictive opioid painkillers.
Blue-181 is a synthetic molecule that’s 50 times more powerful than morphine and works by targeting pain receptors in the spinal chord that reduce the perception of pain.
Though it’s not currently on the market, research for this medication is supported by the National Institutes of Health and the Department of Defense. Researchers hope to be in clinical trials soon.
Are We Handing the House Keys to a Master Thief?
In the meantime, the opioid epidemic rages virtually unimpeded.
Even amidst its legal battles and fines, Purdue Pharma shipped 21 million opioid painkillers to a small West Virginia town – population 2,900 – between 2006 and 2016, crippling an already troubled state.
Handing a patent for opioid addiction treatment to a member of the family that owns Purdue, according to critics, seems like offering a master thief the keys to the house.
You might also be interested in:
Inspire Malibu is the premier Non 12 Step, drug, alcohol, and detox treatment center in Malibu California founded by triple board certified addiction specialist Dr. Akikur Mohammad. Our state-of-the-art treatment program combines the latest scientific research with proven, evidence-based therapies to address both alcohol and substance abuse successfully.
Inspire Malibu is Joint Commission (JCAHO) accredited , Legit Script Certified, and has been designated a Higher Level of Care from the Department of Health Care Services. We are also uniquely qualified to address dual diagnosis disorders.